Argonaute2蛋白及其在人类肿瘤研究中的新进展

doi:10.6040/j.issn.1673-3770.0.2016.485

摘要/Abstract

摘要： 蛋白质组学迅猛发展,越来越多与肿瘤发生发展相关的蛋白质被发现,并被应用于临床诊断。Argonaute2蛋白通过参与构成RNA诱导的沉默复合体,其自身催化及自身过表达功能,在人类肿瘤的发生发展中扮演了重要角色,逐渐成为研究焦点。就Argonaute2蛋白结构、功能及在肿瘤中的作用机制方面的研究新进展做一综述。

关键词: Argonaute2蛋白, GW182, 肿瘤, 翻译后修饰, RNA诱导的沉默复合体

Abstract: With the rapid development of proteomics, proteins related to tumorigenesis and progression have been continuously discovered and applied to clinical diagnosis. By constituting RNA-induced silencing complex(RISC), selfcatalysis and overexpression, Argonaute2 plays an important role in human tumorigenesis and progression, and is becoming a research focus. In this article, we will review the research advances on the structure, function and mechanism of Argonaute2 in tumor development.

Key words: GW182, Tumor, RNA-induced silencing complex, Post-translational modification, Argonaute2

中图分类号:

R767.19

张彦惠综述, 董频审校. Argonaute2蛋白及其在人类肿瘤研究中的新进展[J]. 山东大学耳鼻喉眼学报, 2017, 31(3): 95-99.

ZHANG Yanhui, DONG Pin. Research advances on Argonaute2 and its role in human tumors.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(3): 95-99.

参考文献

[1] Sasaki T, Shiohama A, Minoshima S, et al. Identification of eight members of the Argonaute family in the human genome[J]. Genomics, 2003, 82(3):323-330.
[2] Hutvagner G, Simard MJ. Argonaute proteins: key players in RNA silencing[J]. Nat Rev Mol Cell Biol, 2008, 9(1):22-32.
[3] Schirle NT, MacRae IJ. The crystal structure of human argonaute2[J]. Science, 2012, 336(6084):1037-1040.
[4] Lingel A, Simon B, Izaurralde E, et al. Nucleic acid 3'-end recognition by the Argonaute2 PAZ domain[J]. Nat Struct Mol Biol, 2004, 11(6):576-577.
[5] Liu J, Carmell MA, Rivas FV, et al. Argonaute2 is the catalytic engine of mammalian RNAi[J]. Science, 2004, 305(5689):1437-1441.
[6] Jinek M, Doudna JA. A three-dimensional view of the molecular machinery of RNA interference[J]. Nature, 2009, 457(7228):405-412.
[7] Simon B, Kirkpatrick JP, Eckhardt S, et al. Recognition of 2'-O-methylated 3'-end of piRNA by the PAZ domain of a Piwi protein[J]. Structure, 2011, 19(2):172-180.
[8] Martinez J, Tuschl T. RISC is a 5' phosphomonoester-producing RNA endonuclease[J]. Genes Dev, 2004, 18(9):975-980.
[9] Nam S, Ryu H, Son WJ, et al. Mg2+ effect on argonaute and RNA duplex by molecular dynamics and bioinformatics implications[J]. PloS One, 2014, 9(10):e109745.
[10] Ye X, Huang N, Liu Y, et al. Structure of C3PO and mechanism of human RISC activation[J]. Nat Struct Mol Biol, 2011, 18(6):650-657.
[11] Liu Y, Ye X, Jiang F, et al. C3PO, an endoribonuclease that promotes RNAi by facilitating RISC activation[J]. Science, 2009, 325(5941):750-753.
[12] De N, Young L, Lau PW, et al. Highly complementary target RNAs promote release of guide RNAs from human Argonaute2[J]. Mol Cell, 2013, 50(3):344-355.
[13] Eulalio A, Helms S, Fritzsch C, et al. A C-terminal silencing domain in GW182 is essential for miRNA function[J]. RNA, 2009, 15(6):1067-1077.
[14] Baillat D, Shiekhattar R. Functional dissection of the human TNRC6(GW182-related)family of proteins[J]. Mol Cell Biol, 2009, 29(15):4144-4155.
[15] Behm-Ansmant I, Rehwinkel J, Doerks T, et al. mRNA degradation by miRNAs and GW182 requires both CCR4: NOT deadenylase and DCP1: DCP2 decapping complexes[J]. Genes Dev, 2006, 20(14):1885-1898.
[16] Boland A, Huntzinger E, Schmidt S, et al. Crystal structure of the MID-PIWI lobe of a eukaryotic Argonaute protein[J]. Proc Natl Acad Sci U S A, 2011, 108(26):10466-10471.
[17] Jakymiw A, Lian S, Eystathioy T, et al. Disruption of GW bodies impairs mammalian RNA interference[J]. Nat Cell Biol, 2005, 7(12):1267-1274.
[18] Lian SL, Li S, Abadal GX, et al. The C-terminal half of human Ago2 binds to multiple GW-rich regions of GW182 to mediate silencing[J]. RNA, 2009, 15(5):804-813.
[19] Liu J, Rivas FV, Wohlschlegel J, et al. A role for the P-body component GW182 in microRNA function[J]. Nat Cell Biol, 2005, 7(12):1261-1266.
[20] Meister G, Landthaler M, Peters L, et al. Identification of novel argonaute-associated proteins[J]. Curr Biol, 2005, 15(23):2149-2155.
[21] Zeng Y, Sankala H, Zhang X, et al. Phosphorylation of Argonaute2 at serine-387 facilitates its localization to processing bodies[J]. Biochem J, 2008, 413(3):429-436.
[22] Rüdel S, Wang Y, Lenobel R, et al. Phosphorylation of human Argonaute proteins affects small RNA binding[J]. Nucleic Acids Res, 2011, 39(6):2330-2343.
[23] Horman SR, Janas MM, Litterst C, et al. Akt-mediated phosphorylation of argonaute2 downregulates cleavage and upregulates translational repression of MicroRNA targets[J]. Mol Cell, 2013, 50(3):356-367.
[24] Winter J, Diederichs S. Argonaute proteins regulate microRNA stability: increased microRNA abundance by Argonaute proteins is due to microRNA stabilization[J]. RNA Biol, 2011, 8(6):1149-1157.
[25] Martine NJ, Gregory RI. Argonaute2 expression is post-transcriptionally coupled to microRNA abundance[J]. RNA, 2013, 19(5):605-612.
[26] Shen J, Xia W, Khotskaya YB, et al. EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2[J]. Nature, 2013, 497(7449):383-387.
[27] Qi HH, Ongusaha PP, Myllyharju J, et al. Prolyl 4-hydroxylation regulates Argonaute 2 stability[J]. Nature, 2008, 455(7211):421-424.
[28] Rybak A, Fuchs H, Hadian K, et al. The let-7 target gene mouse lin-41 is a stem cell specific E3 ubiquitin ligase for the miRNA pathway protein Ago2[J]. Nat Cell Biol, 2009, 11(12):1411-1420.
[29] Sahin U, Lapaquette P, Andrieux A, et al. Sumoylation of human argonaute2 at lysine-402 regulates its stability[J]. PLoS One, 2014, 9(7):e102957.
[30] Cheng N, Li Y, Han ZG. Argonaute2 promotes tumor metastasis by way of up-regulating focal adhesion kinase expression in hepatocellular carcinoma[J]. Hepatology, 2013, 57(5):1906-1918.
[31] Papachristou DJ, Korpetinou A, Giannopoulou E, et al. Expression of the ribonucleases Drosha, Dicer, and Ago2 in colorectal carcinomas[J]. Virchows Arch, 2011, 459(4):431-440.
[32] Li L, Yu C, Gao H, et al. Argonaute proteins: potential biomarkers for human colon cancer[J]. BMC Cancer, 2010, 10:38.
[33] Zhang J, Fan XS, Wang CX, et al. Up-regulation of Ago2 expression in gastric carcinoma[J]. Med Oncol, 2013, 30(3):628.
[34] Adams BD, Claffey KP, White BA. Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells[J]. Endocrinology, 2009, 150(1):14-23.
[35] Bian XJ, Zhang GM, Gu CY, et al. Down-regulation of Dicer and Ago2 is associated with cell proliferation and apoptosis in prostate cancer[J]. Tumour Biol, 2014, 35(11):11571-11578.
[36] Vaksman O, Hetland TE, Trope' CG, et al. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma[J]. Hum Pathol, 2012, 43(11):2062-2069.
[37] Yang FQ, Huang JH, Liu M, et al. Argonaute2 is up-regulated in tissues of urothelial carcinoma of bladder[J]. Int J Clin Exp Pathol, 2013, 7(1):340-347.
[38] Iosue I, Quaranta R, Masciarelli S, et al. Argonaute2 sustains the gene expression program driving human monocytic differentiation of acute myeloid leukemia cells[J]. Cell Death Dis, 2013, 4:e926.
[39] Naoqhare PK, Tak YK, Kim MJ, et al. Knock-down of argonaute2(AGO2)induces apoptosis in myeloid leukaemia cells and inhibits siRNA-mediated silencing of transfected oncogenes in HEK-293 cells[J]. Basic Clin Pharmacol Toxicol, 2011, 109(4):274-282.
[40] Asai T, Suzuki Y, Matsushita S, et al. Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown[J]. Biochem Biophys Res Commun, 2008, 368(2):243-248.
[41] Chang SS, Smith I, Glazer C, et al. EIF2C is overexpressed and amplified in head and neck squamous cell carcinoma[J]. ORL J Otorhinolaryngol Relat Spec, 2010, 72(6):337-343.
[42] Sand M, Skrygan M, Georgas D, et al. Expression levels of the microRNA maturing microprocessor complex component DGCR8 and the RNA-induced silencing complex(RISC)components argonaute-1, argonaute-2, PACT, TARBP1, and TARBP2 in epithelial skin cancer[J]. Mol Carcinog, 2012, 51(11):916-922.
[43] Carouge D, Blanc V, Knoblaugh SE, et al. Parent-of-origin effects of A1CF and AGO2 on testicular germ-cell tumors, testicular abnormalities, and fertilization bias[J]. Proc Natl Acad Sci U S A, 2016, 113(37):E5425-E5433.
[44] Murray MJ, Nicholson JC, Coleman N. Biology of childhood germ cell tumours,focussing on the significance of microRNAs[J]. Andrology, 2015, 3(1):129-139.
[45] Guo J, Lv J, Liu M, et al. miR-346 up-regulates Argonaute 2(AGO2)protein expression to augment the activity of other microRNAs(miRNAs)and contributes to cervical cancer cell malignancy[J]. J Biol Chem, 2015, 290(51):30342-30350.
[46] Wu S, Yu W, Qu X, et al. Argonaute2 promotes myeloma angiogenesis via microRNA dysregulation[J]. J Hematol Oncol, 2014, 7(1):40.
[47] Xu Q, Hou YX, Langlais P, et al. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival[J]. BMC Cancer, 2016, 16(1):1-16.
[48] Krell J, Stebbing J, Carissimi C, et al. TP53 regulates miRNA association with AGO2 to remodel the miRNA-mRNA interaction network[J]. Genome Res, 2016, 26(3):331-341.
[49] Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M, et al. miRNA biogenesis: biological impact in the development of cancer[J]. Cancer Biol Ther, 2014, 15(11):1444-1455.
[50] Yang M, Haase AD, Huang FK, et al. Dephosphorylation of tyrosine 393 in argonaute 2 by protein tyrosine phosphatase 1B regulates gene silencing in oncogenic RAS-induced senescence[J]. Mol Cell, 2014, 55(5):782-790.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed